Oligonucleotide Therapies for the Lung: Ready to Return to the Clinic?
作者信息
Kumar Manish, Moschos Sterghios A
机构信息
Northumbria University, Faculty of Health and Life Sciences, Newcastle, Tyne and Wear NE1 8ST, UK.
Northumbria University, Faculty of Health and Life Sciences, Newcastle, Tyne and Wear NE1 8ST, UK.
出版信息
Mol Ther. 2017 Dec 6;25(12):2604-2606. doi: 10.1016/j.ymthe.2017.11.002. Epub 2017 Nov 23.
Abstract
摘要
相似文献
1
Oligonucleotide Therapies for the Lung: Ready to Return to the Clinic?
Mol Ther. 2017 Dec 6;25(12):2604-2606. doi: 10.1016/j.ymthe.2017.11.002. Epub 2017 Nov 23.
2
Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice.
J Cyst Fibros. 2017 Nov;16(6):671-680. doi: 10.1016/j.jcf.2017.05.003. Epub 2017 May 20.
3
Antisense oligonucleotide inhibition of heat shock protein (HSP) 47 improves bleomycin-induced pulmonary fibrosis in rats.
Respir Res. 2007 May 15;8(1):37. doi: 10.1186/1465-9921-8-37.
4
Oligonucleotide-targeting periostin ameliorates pulmonary fibrosis.
Gene Ther. 2017 Nov;24(11):706-716. doi: 10.1038/gt.2017.80. Epub 2017 Aug 18.
5
Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides.
Hum Mutat. 2016 Feb;37(2):209-15. doi: 10.1002/humu.22931. Epub 2015 Dec 2.
6
Antisense oligonucleotides to NF-kappaB improve survival in bleomycin-induced pneumopathy of the mouse.
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1561-8. doi: 10.1164/ajrccm.162.4.9908093.
7
Pharmacokinetics of antisense oligonucleotides.
Clin Pharmacokinet. 1995 Jan;28(1):7-16. doi: 10.2165/00003088-199528010-00002.
8
An antisense oligonucleotide to HSP47 inhibits paraquat-induced pulmonary fibrosis in rats.
Toxicology. 2007 Jul 17;236(3):199-207. doi: 10.1016/j.tox.2007.04.013. Epub 2007 May 1.
9
New horizons for cystic fibrosis treatment.
Pharmacol Ther. 2017 Feb;170:205-211. doi: 10.1016/j.pharmthera.2016.11.009. Epub 2016 Dec 1.
引用本文的文献
1
Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV.
Mol Ther Nucleic Acids. 2025 May 20;36(3):102572. doi: 10.1016/j.omtn.2025.102572. eCollection 2025 Sep 9.
2
Current and future therapeutic approaches of CFTR and airway dysbiosis in an era of personalized medicine.
J Family Med Prim Care. 2024 Jun;13(6):2200-2208. doi: 10.4103/jfmpc.jfmpc_1085_23. Epub 2024 Jun 14.
3
Aerosol pulmonary immune engineering.
Adv Drug Deliv Rev. 2023 Aug;199:114831. doi: 10.1016/j.addr.2023.114831. Epub 2023 Apr 24.
4
Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics.
Nucleic Acids Res. 2023 Feb 28;51(4):1583-1599. doi: 10.1093/nar/gkad023.
5
Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.
J Cyst Fibros. 2023 Mar;22 Suppl 1(Suppl 1):S39-S44. doi: 10.1016/j.jcf.2022.12.016. Epub 2023 Jan 17.
6
The Idiopathic Pulmonary Fibrosis-Associated Single Nucleotide Polymorphism RS35705950 Is Transcribed in a MUC5B Promoter Associated Long Non-Coding RNA (AC061979.1).
Noncoding RNA. 2022 Dec 8;8(6):83. doi: 10.3390/ncrna8060083.
7
Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics.
RSC Adv. 2022 Jul 14;12(32):20432-20446. doi: 10.1039/d2ra01999j.
8
Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.
J Cyst Fibros. 2021 Sep;20(5):865-875. doi: 10.1016/j.jcf.2021.06.003. Epub 2021 Jul 2.
本文引用的文献
1
The SMA Trust: the role of a disease-focused research charity in developing treatments for SMA.
Gene Ther. 2017 Sep;24(9):544-546. doi: 10.1038/gt.2017.47. Epub 2017 May 31.
2
Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice.
J Cyst Fibros. 2017 Nov;16(6):671-680. doi: 10.1016/j.jcf.2017.05.003. Epub 2017 May 20.
3
Nucleic Acid Immunity.
Adv Immunol. 2017;133:121-169. doi: 10.1016/bs.ai.2016.11.001. Epub 2016 Dec 15.
4
Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes.
AAPS J. 2017 May;19(3):652-668. doi: 10.1208/s12248-017-0054-z. Epub 2017 Feb 13.
5
Clinical potential of oligonucleotide-based therapeutics in the respiratory system.
Pharmacol Ther. 2017 Jan;169:83-103. doi: 10.1016/j.pharmthera.2016.10.009. Epub 2016 Oct 19.
6
Destabilization of Lysophosphatidic Acid Receptor 1 Reduces Cytokine Release and Protects Against Lung Injury.
EBioMedicine. 2016 Aug;10:195-203. doi: 10.1016/j.ebiom.2016.07.020. Epub 2016 Jul 18.
7
Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides.
Hum Mutat. 2016 Feb;37(2):209-15. doi: 10.1002/humu.22931. Epub 2015 Dec 2.
8
Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration.
PLoS One. 2015 Sep 9;10(9):e0137504. doi: 10.1371/journal.pone.0137504. eCollection 2015.
9
Resident alveolar macrophages suppress, whereas recruited monocytes promote, allergic lung inflammation in murine models of asthma.
J Immunol. 2014 Oct 15;193(8):4245-53. doi: 10.4049/jimmunol.1400580. Epub 2014 Sep 15.
10
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Nucleic Acids Res. 2014 Jul;42(13):8796-807. doi: 10.1093/nar/gku531. Epub 2014 Jul 3.
Zotero 插件